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Iron Overload during Follow-up after Tandem High-Dose 
Chemotherapy and Autologous Stem Cell Transplantation  
in Patients with High-Risk Neuroblastoma
Multiple RBC transfusions inevitably lead to a state of iron overload before and after high-
dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT). 
Nonetheless, iron status during post-SCT follow-up remains unknown. Therefore, we 
investigated post-SCT ferritin levels, factors contributing to its sustained levels, and organ 
functions affected by iron overload in 49 children with high-risk neuroblastoma who 
underwent tandem HDCT/autoSCT. Although serum ferritin levels gradually decreased 
during post-SCT follow-up, 47.7% of the patients maintained ferritin levels above 1,000 
ng/mL at 1 yr after the second HDCT/autoSCT. These patients had higher serum creatinine 
(0.62 vs 0.47 mg/mL, P = 0.007) than their counterparts ( < 1,000 ng/mL). Post-SCT 
transfusion amount corresponded to increased ferritin levels at 1 yr after the second HDCT/
autoSCT (P < 0.001). A lower CD34
+ cell count was associated with a greater need of RBC 
transfusion, which in turn led to a higher serum ferritin level at 1 yr after HDCT/autoSCT. 
The number of CD34
+ cells transplanted was an independent factor for ferritin levels at 
1 yr after the second HDCT/autoSCT (P = 0.019). Consequently, CD34
+ cells should be 
transplanted as many as possible to prevent the sustained iron overload after tandem 
HDCT/autoSCT and consequent adverse effects.
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INTRODUCTION
The use of high-dose chemotherapy in conjunction with autol-
ogous stem cell transplantation (HDCT/autoSCT) has been dem-
onstrated to increase the survival rate of children with high-risk 
solid tumors (1). Several researchers have recently shown that 
tandem HDCT/autoSCT may also be a feasible method of im-
proving the treatment outcome (2-5). This approach is based 
on the underlying hypothesis that additional dose escalation is 
likely to further enhance the survival of children with high-risk 
solid tumors. Patients who undergo HDCT/autoSCT generally 
require frequent RBC transfusions not only during induction 
chemotherapy but also during post-SCT period until engraft-
ment. Consequently, high-risk solid tumor patients who have 
received tandem HDCT/autoSCT generally experience iron 
overload. Dose escalation during tandem HDCT/autoSCT may 
also be associated with higher frequencies of acute and chronic 
toxicities, including toxicities from iron overload.
  Much attention has been given to acute adverse effects of ear-
ly post-SCT iron overload including hepatic veno-occlusive dis-
ease, infections, and idiopathic pneumonia syndrome (3, 4). 
Elevated serum ferritin level has also corresponded to increased 
SCT-related mortality and decreased overall survival rate (4-8). 
However, late adverse effects of post-SCT iron overload remain 
inconclusive. While detrimental effects of transfusional iron over-
load including abnormal liver function test, hepatic fibrosis/
cirrhosis, cardiac dysfunction, and susceptibility to infection 
have been suggested in patients with chronic acquired anemias 
(9, 10), the effects of transfusional iron overload during post-
SCT follow-up period remain unclear.
  As SCT recipients do not require RBC transfusion after engraft-
ment, their iron levels are expected to decrease over time, par-
ticularly in growing children, unlike chronic anemia patients 
who require life-long transfusion and thus have sustained iron 
overload. Nevertheless, when iron overload is sustained in SCT 
recipients, its adverse effects may be more pronounced than in Bae SJ, et al.  •  Iron Overload after Tandem HDCT/autoSCT
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chronic anemia patients, either in onset or severity, due to pre-
vious cytotoxic chemoradiotherapy. However, iron status in 
children during follow-up after tandem HDCT/autoSCT and its 
adverse effects are, to our knowledge, unknown. Therefore, the 
present study investigated the trend of iron levels at various time 
points during follow-up for more than 3 yr after tandem HDCT/ 
autoSCT in children with high-risk neuroblastoma and factors 
contributing to its sustained levels, as well as major organ func-
tions affected by iron overload.
MATERIALS AND METHODS
Patients
Children with high-risk neuroblastoma who underwent tandem 
HDCT/autoSCT between January 2006 and June 2010 were eligi-
ble for the present retrospective analysis. Intermediate-risk pa-
tients with relapsed tumor or intermediate-risk patients showing 
inadequate response to conventional chemoradiotherapy also un-
derwent tandem HDCT/autoSCT and were eligible for the study. 
Treatment prior to HDCT/autoSCT
Patients received nine cycles of induction chemotherapy prior 
to tandem HDCT/autoSCT. The CEDC and ICE regimens were 
used in an alternating manner (Table 1). Definitive surgery was 
performed after the sixth chemotherapy cycle except for those 
patients who had undergone a surgical resection before the ad-
ministration of induction chemotherapy. Each chemotherapy 
cycle was scheduled to be 28 days apart, but delays less than 2 
weeks were permitted to allow the absolute neutrophil count 
(ANC) and platelet count to recover to 1,000/µL and 100,000/µL, 
respectively. If chemotherapy was delayed for more than 2 weeks, 
doses were reduced by 25% of the calculated dose. 
Tandem HDCT/autoSCT
After the completion of induction therapy, patients underwent 
tandem HDCT/autoSCT. Table 1 lists the HDCT regimens. Brief-
ly, CEC regimen was employed for the first HDCT. The regimens 
for the second HDCT were TM-TBI or TM in the early period 
(until December 2009) and high-dose 
131I-MIBG (metaiodo- 
benzylguanidine)-TM or TM in the late period (from January 
2010). TBI or high-dose 
131I-MIBG treatment was included in 
the second HDCT only for stage 4 patients. There was a 12-week 
interval between the first and second HDCT/autoSCT. Approxi-
mately half of the collected peripheral blood stem cells were in-
fused for marrow rescue at each HDCT session.
Transfusion and iron chelation treatment
Generally, irradiated, packed RBCs were transfused when hemo-
globin level fell below 8.0 g/dL. Nevertheless, we tried to main-
tain a hemoglobin level over 10.0 g/dL if the patient underwent 
surgery, suffered from high fever, or required oxygen supply for 
any reason. Normally, 10 mL/kg of RBCs were transfused each 
time. No patient received iron chelation treatment during or af-
ter tandem HDCT/autoSCT in the present study.
Iron level monitoring
Serum ferritin was measured before each HDCT/autoSCT and 
at 1, 3, 6, 9, 12, 16, 20, 24, 30, and 36 months after the second 
HDCT/autoSCT. Serum ferritin levels in patients with relapsed 
tumor during follow-up after tandem HDCT/autoSCT were ex-
cluded from analysis because tumor relapse and treatment after 
relapse can affect serum ferritin level. 
Table 1. Induction and high-dose chemotherapy regimens
Regimen Drug                          Dose Schedule
Induction regimens
   CEDC
 
 
 
   ICE  
 
 
 
Cisplatin
Etoposide
Doxorubicin
Cyclophophamide
Ifosfamide
Carboplatin
Etoposide
 
60 mg/m
2/day
100 mg/m
2/day
30 mg/m
2/day
30 mg/kg/day
1,200 mg/m
2/day
400 mg/m
2/day
100 mg/m
2/day
 
Day 0
Days 2 & 5
Day 2
Days 3 & 4
Days 0–4
Days 0 & 1
Days 0–4
First HDCT regimen
   CEC
 
 
 
Carboplatin
Etoposide
Cyclophosphamide
 
650 mg/m
2/day
650 mg/m
2/day
1,800 mg/m
2/day
 
Days –7, –6, –5
Days –7, –6, –5
Days –4, –3, –2
Second HDCT regimens
   TM-TBI
 
 
   MIBG-TM
 
 
   TM
 
 
Thiotepa
Melphalan
TBI
131I-MIBG
Thiotepa
Melphalan
Thiotepa
Melphalan
 
200 mg/m
2/day
60 mg/m
2/day
 3.33 Gy/day
12-18 mCi/kg
200 mg/m
2/day
60 mg/m
2/day
300 mg/m
2/day
60 mg/m
2/day
 
Days –8, –7, –6
Days –5 & –4
Days –3, –2, –1
Day –21
Days –6, –5, –4
Days –3 & –2
Days –6, –5, –4
Days –3 & –2
HDCT, High-dose chemotherapy; TBI, Total-body irradiation; MIBG, Metaiodobenzylguanidine.Bae SJ, et al.  •  Iron Overload after Tandem HDCT/autoSCT
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Organ function test
Major organ functions were evaluated at 1 yr after the second 
HDCT/autoSCT. Chest X-ray, electrocardiogram, and echocar-
diogram were performed to determine cardiac and pulmonary 
functions. Renal glomerular and tubular functions were also 
evaluated. Growth hormone, thyroid hormone, cortisol, and 
sex hormone levels were measured to assess endocrine func-
tion. Ophthalmological and auditory functions were also exam-
ined. Patients who had a relapsed tumor within 1 yr after tan-
dem HDCT/autoSCT were excluded from organ function anal-
ysis since they received salvage treatment after relapse, which 
can deteriorate organ function. Organ dysfunction was assessed 
using the Common Toxicity Criteria of National Cancer Insti-
tute of the USA. Major organ functions at 1 yr after the second 
HDCT/autoSCT were compared according to the ferritin level 
( > 1,000 vs < 1,000 ng/mL) at 1 yr after the second HDCT/au-
toSCT.
Statistics
Differences in the frequencies of various toxicities between the 
two groups according to the ferritin level were analyzed using 
the Pearson chi-square test. Spearman test was performed to 
evaluate the correlation between the two continuous variables. 
Differences in the continuous variables between the two groups 
were compared using the Mann-Whitney U-test. Multivariate 
analysis was also performed using linear regression analysis to 
examine the factors associated with ferritin levels at 1 yr after 
the second HDCT/autoSCT. P values < 0.05 were considered 
significant.
Ethics statements
The study protocol was approved by the institutional review 
board of Samsung Medical Center (IRB No. 2011-09-103). In-
formed consent was waived by the board. 
RESULTS
Patient characteristics
During study period, 49 neuroblastoma patients underwent 
tandem HDCT/autoSCT. Forty-one of them had high-risk neu-
roblastoma, 5 had intermediate-risk neuroblastoma showing 
inadequate response to induction treatment, and the remaining 
3 had relapsed neuroblastoma. The age at diagnosis or relapse 
was a median of 31 (range 1-120) months. Thirty-five patients 
had a stage 4 tumor, 17 had a MYCN amplified tumor, and 25 
had a tumor with unfavorable histology.
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Fig. 1. Serum ferritin during post-SCT follow-up. (A) Serum ferritin level peaks at one 
month after the second HDCT/autoSCT and steadily decreases without iron chelation. 
(B) Ferritin level at 1 yr after the second HDCT/autoSCT remaines high and 47.7% of 
the patients had ferritin levels greater than 1,000 ng/mL. (C) Serum ferritin level at     
1 yr after the second HDCT/autoSCT has a positive correlation with RBC transfusion 
amount during 1 yr after the second HDCT/autoSCT . Bae SJ, et al.  •  Iron Overload after Tandem HDCT/autoSCT
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Transfusion amount before and after tandem HDCT/autoSCT
The cumulative RBC transfusion amount prior to the first HDCT/ 
autoSCT was a median of 166 (range 77-251) mL/kg. RBC trans-
fusion amount between the first and second HDCT/autoSCT 
was a median of 38 (range 16-190) mL/kg with the cumulative 
RBC transfusion amount prior to the second HDCT/autoSCT 
being a median of 213 (range 94-352) mL/kg. RBC transfusion 
amount for 1 yr after the second HDCT/autoSCT was a median 
of 65 (range 0-580) mL/kg with the cumulative RBC transfusion 
amount until 1 yr after the second HDCT/autoSCT being a me-
dian of 286 (range 91-895) mL/kg.
Ferritin levels during follow-up after tandem HDCT/
autoSCT
Median serum ferritin levels prior to the first and second HDCT/ 
autoSCT were 1,389 (range 226-2,629) ng/mL and 1,205 (range 
129-3,040) ng/mL, respectively. Serum ferritin level peaked at 
one month after the second HDCT/autoSCT (median 2,297  
ng/mL) and steadily decreased to a median of 285 ng/mL at       
36 months after the second HDCT/autoSCT without iron che-
lation. However, ferritin level at 1 yr after the second HDCT/au-
toSCT remained high at a median of 792 (range 52-4,652) ng/mL 
and 47.7% of the patients had ferritin levels greater than 1,000 
ng/mL (Fig. 1A, B). Serum ferritin level at 1 yr after the second 
HDCT/autoSCT had a positive correlation with RBC transfusion 
amount during 1 yr after the second HDCT/autoSCT (P < 0.001, 
Fig. 1C). 
Ferritin level and major organ function
Table 2 lists grade 3/4 organ dysfunction at 1 yr after the second 
HDCT/autoSCT according to ferritin levels at 1 yr after the sec-
ond HDCT/autoSCT ( < 1,000 vs  > 1,000 ng/mL). There was no 
difference in serum creatinine and creatinine clearance levels 
prior to the second HDCT/autoSCT between the two groups. 
However, serum creatinine level was significantly higher in pa-
tients with high ferritin levels than their counterparts (median 
0.62 vs 0.47 mg/mL, P = 0.007), and similarly, creatinine clear-
ance was lower than their counterparts with borderline signifi-
cance (52.2 vs 70.1 mL/min/1.73m
2, P = 0.087) (Fig. 2A). There 
was no difference in the frequency of renal tubular dysfunction. 
Alanine aminotransferase level was also higher in patients with 
high ferritin levels (P = 0.011, Fig. 2B), even though its clinical 
significance might not be significant. Otherwise, there was no 
difference in the frequencies of organ dysfunctions between 
the two groups. 
Effect of CD34
+ cell number on RBC transfusion amount 
and ferritin level
A median of 2.3 (range 0.6-15.6) × 10
6 CD34
+ cells/kg were in-
fused for the first HDCT/autoSCT, and the median times required 
Table 2. Organ dysfunction according to ferritin level at 1 yr after tandem HDCT/au-
toSCT
Parameters
< 1,000 (ng/mL) 
(n = 23)
> 1,000 (ng/mL) 
(n = 20)
P value
Renal dysfunction
   SCr (mg/dL)
   CCr (mL/min/1.73m
2)
   Renal tubular acidosis
 
0.47 (0.22-0.82)*
 70.1 (22.2-153.9)
     4 (17.4%)
 
0.62 (0.37-5.7)
  52.2 (6.9-153.4)
      5 (25.0%)
 
0.007
0.087
0.541
Liver dysfunction
   Bilirubin (mg/mL)
   AST (U/mL)
   ALT (U/mL)
 
   0.3 (0.2-0.8)
  33 (23-69)
  22 (12-40)
 
    0.3 (0.2-0.8)
35.5 (21-78)
  29.5 (10-181)
 
0.435
0.414
0.011
Endocrine dysfunction
   Growth hormone deficiency
   Thyroid hormone deficiency
   Glucocorticoid deficiency
   Sex hormone deficiency
 
0 (0%)
     7 (30.4%)
0 (0%)
0 (0%)
 
 0 (0%)
      7 (35.0%)
    1 (5.0%)
 0 (0%)
 
1.000
0.750
0.278
1.000
Congestive heart failure 0 (0%)  0 (0%) 1.000
Pulmonary dysfunction 0 (0%)  0 (0%) 1.000
Ophthalmological dysfunction 0 (0%)  0 (0%) 1.000
Sensory neural hearing loss    2 (8.7%)     1 (5.0%) 0.635
*Median (range). SCr, Serum creatinine; CCr, Creatinine clearance; AST, Aspartate 
aminotransferase; ALT, Alanine aminotransferase.
Fig. 2. Organ dysfunction at 1 yr after the second HDCT/autoSCT. There was no difference in major organ function prior to the second HDCT/autoSCT between the two groups. 
However, serum creatinine level (A) and alanine aminotransferase level (B) are significantly higher in patients with high ferritin levels at 1 yr after the second HDCT/autoSCT. 
P = 0.007
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Table 3. Factors affecting ferritin level at 1 yr after the second HDCT/autoSCT
Variables
RBC transfusion amount
for 1 yr after the second HDCT/autoSCT
Serum ferritin level
at 1 yr after the second HDCT/autoSCT
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Amount (mL/kg) P value t-score P value Ferritin (ng/mL) P value t-score P value
Age at HDCT2
   < 3 yr (n = 19)
   > 3 yr (n = 24)
 
  29 (8-474)
120 (0-580)
 
 
0.008
 
 
-0.028
 
 
0.978
 
 611 (52-2,949)
1,238 (339-4,652)
 
 
0.010
 
 
1.185
 
 
0.243
TBI
   No (n = 20)
   Yes (n = 23)
  29 (0-249)
  111 (21-580)
  
0.002
 
 
 2.017
 
 
0.050
 
 611 (52-3,441)
1,238 (141-4,652)
 
 
0.022
 
 
0.403
 
 
0.689
CD34+ cells
   > 2 × 10
6/kg (n = 26)
   < 2 × 10
6/kg (n = 17)
 
  40 (0-474)
  148 (26-580)
 
0.003
 
 
 2.306
 
 
0.026
 
 609 (52-2,949)
1,319 (233-4,652)
 
 
0.005
 
 
2.445
 
 
0.019
TBI, Total-body irradiation.
to reach an ANC of 500/μL and a platelet count of 20,000/μL 
without transfusion for the previous 7 days were 11 days (range 
8-35) and 25 days (range 15-68), respectively. A median of 2.4 
(range 1.0-16.0) × 10
6 CD34
+ cells/kg were infused for the sec-
ond HDCT/autoSCT and the median times required to reach 
an ANC of 500/μL and a platelet count of 20,000/μL were 11 days 
(range 7-16) and 36.5 days (range 14-322), respectively. 
  A less number of CD34
+ cells ( < 2 × 10
6/kg) in the second 
HDCT/autoSCT was associated with a slower recovery of neu-
trophil and platelet (median 12 vs 10 days, P < 0.001; median 
115 vs 21.5 days, P < 0.001). In addition, it was associated with  
a greater amount of RBC transfusion for 1 yr after the second 
HDCT/autoSCT (P = 0.003, Fig. 3A) and accordingly, a higher 
ferritin level at 1 yr after the second HDCT/autoSCT (P = 0.005, 
Fig. 3B). 
Factors affecting post-SCT ferritin level 
Age older than 3 yr at the second HDCT/autoSCT, inclusion of 
TBI in the second HDCT/autoSCT, and transplantation with 
low number of CD34
+ cells (< 2 × 10
6/kg) were associated with 
greater RBC transfusion amount for 1 yr after the second HDCT/ 
autoSCT and higher ferritin levels at 1 yr after the second HDCT/ 
autoSCT in the univariate analysis (Table 3). In the multivariate 
analysis, low number of CD34
+ cells (< 2 × 10
6/kg) in the sec-
ond HDCT/autoSCT was the only independent factor for great-
er RBC transfusion amount for 1 yr after the second HDCT/au-
toSCT and higher ferritin levels at 1 yr after the second HDCT/
autoSCT (P = 0.026 and P = 0.019, respectively). 
 
DISCUSSION
In the past, much research had been focused on iron overload 
and its adverse effects caused solely by multiple blood transfu-
sions in diseases such as beta-thalassemia major and other 
chronic anemia (11-13). Recently, as the number of survivors 
with high-risk malignancy increases, particularly after SCT which 
requires multiple transfusions during pre- and post-SCT peri-
od, iron overload has become an increasingly important risk 
factor for outcome in these patients (14). Iron overload in SCT 
recipients may have different, more severe manifestations and 
must therefore be evaluated differently from that in chronic 
anemia patients who do not receive chemoradiotherapy. It is 
Fig. 3. Transfusion amount and serum ferritin according to the number of CD34
+ cells. A less number of CD34
+ cells (< 2 × 10
6/kg) in the second HDCT/autoSCT is associated 
with a greater amount of RBC transfusion for 1 yr after the second HDCT/autoSCT (A), and accordingly, a higher ferritin level at 1 yr after the second HDCT/autoSCT (B). 
P = 0.005
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well established that a higher pre-SCT iron level is associated 
with more frequent various toxicities during SCT and a higher 
toxic death rate (15-17). However, studies for iron status and its 
late adverse effects during post-SCT follow-up are very limited 
(18). Thus, our primary objective was to demonstrate the trend 
of iron levels during follow-up at various time points after tan-
dem HDCT/autoSCT in children with high-risk neuroblastoma 
and factors contributing to its sustained levels, as well as major 
organ functions affected by iron overload.
  Because HDCT/autoSCT recipients do not need RBC trans-
fusion after engraftment, iron levels are expected to decrease 
over time, particularly in growing children. Indeed, ferritin levels 
steadily decreased without iron chelation after HDCT/autoSCT 
in the present study. Nevertheless, when the number of CD34
+ 
cells transplanted was low, patients required prolonged RBC 
transfusion after HDCT/autoSCT, and accordingly, their ferritin 
levels at 1 yr after tandem HDCT/autoSCT were high. There 
was a strong correlation between the number of CD34
+ cells 
and RBC transfusion amount during the post-SCT period. A 
lower CD34
+ cell number was associated with a greater need of 
RBC transfusion, which in turn led to higher serum ferritin lev-
els at 1 yr after tandem HDCT/autoSCT. The number of CD34
+ 
cells was an independent factor affecting the ferritin level at 1 yr 
after tandem HDCT/autoSCT. Most clinical reports concerning 
SCT have used neutrophil and platelet recovery as parameters 
for hematologic recovery after SCT. However, findings in the 
present study suggest that RBC recovery should also be consid-
ered as a significant parameter assessing the hematologic re-
covery and outcome after SCT.
  About half of the patients in the present study maintained 
ferritin levels  > 1,000 ng/mL at 1 yr after the tandem HDCT/
autoSCT. In these patients, renal glomerular function was sig-
nificantly worse than their counterparts (ferritin levels < 1,000 
ng/mL) at 1 yr after tandem HDCT/autoSCT. There was no differ-
ence in glomerular function prior to HDCT/autoSCT between 
the two groups. These findings suggest a possible correlation 
between high ferritin levels and impairment of glomerular func-
tion during post-SCT follow-up. However, at present, it is not 
clear if hyperferritinemia is directly responsible for impaired 
glomerular function during post-SCT follow-up because all of 
our patients had received intensive induction and HDCT with 
various nephrotoxic agents, and therefore might already have 
subclinical renal dysfunction after tandem HDCT/autoSCT. 
Longer follow-up and a larger cohort of patients may be needed 
to elucidate if heperferritinemia is responsible for impairment 
of glomerular function during post-SCT follow-up.  
  We previously showed that deferasirox treatment prior to 
tandem HDCT/autoSCT is effective at lowering pre-SCT serum 
ferritin levels, thereby lowering the frequency of hepatic veno-
occlusive disease and infection during tandem HDCT/autoSCT 
in children with neuroblastoma and brain tumors (19). Howev-
er, at present, experience of iron chelation treatment after SCT, 
particularly with deferasirox, is very limited. Elevation of serum 
creatinine levels during deferasirox treatment has frequently 
been reported (19, 20), and the US Food and Drug Administra-
tion (FDA) black box warning for deferasirox includes renal fail-
ure (21). This poses as a challenge in using deferasirox to treat 
iron overload in HDCT/autoSCT recipients, as they may be more 
susceptible to possible adverse effects of iron chelation treat-
ment than chronic anemia patients due to previous chemora-
diotherapy. Furthermore, the present study showed that renal 
glomerular function at 1 yr after tandem HDCT/autoSCT was 
already lower in patients with high ferritin levels. Taken togeth-
er, findings in the present study suggest that the use of iron che-
lators such as deferasirox should be approached with caution 
in patients who underwent HDCT/autoSCT.
  We used serum ferritin as a measure of iron overload in the 
present study because repeated measurements can be per-
formed without difficulty to establish trends in iron burden 
over time. However, previous publications have suggested that 
this may not be a reliable indicator of iron overload (22). Serum 
ferritin may be increased due to liver dysfunction, may act as an 
acute phase reactant of infectious complications, and may be 
increased in other SCT-related complications. More specific 
measures of iron overload include liver MRI and liver biopsy. 
Therefore, it may be important in further testing our hypothesis 
to use liver biopsy or MRI to better quantify iron overload.
  In summary, we demonstrated for the first time that ferritin 
levels sustained high even at 1 yr after tandem HDCT/autoSCT 
when the number of CD34
+ cells transplanted was low, and ac-
cordingly, patients required prolonged RBC transfusion after 
HDCT/autoSCT. We acknowledge the limitations present in 
our small single-institution study and believe that further vali-
dation in patients with other solid tumors and a longer follow-
up period for assessing organ function are necessary. Nonethe-
less, our results strongly support the notion that further modali-
ties of collecting more CD34
+ cells must be researched in order 
to reduce RBC transfusion amount, lower ferritin level, and pos-
sibly decrease organ dysfunction related to iron overload in pa-
tients with high-risk solid tumors.
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